NCT07651293Toborzás még nem indult
Using Fenfluramine to Test the Serotonin Deficiency Theory of Depression
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jún. 16.
Rövid összefoglaló (regiszter, angolul)
Clinical depression is a common and disabling condition characterised by persistent low mood and loss of interest that interferes with daily functioning. Serotonin is a key brain neurotransmitter involved in mood regulation, and a leading theory proposes that depression is associated with impaired serotonin function (the serotonin deficiency hypothesis), which underpins the use of selective serotonin reuptake inhibitors (SSRIs) as first-line antidepressant treatments. However, the strength and specificity of the link between serotonin dysfunction and depressive symptoms in humans remains uncertain and requires direct evidence in living human brains. Positron Emission Tomography (PET) allows in vivo quantification of neurotransmitter receptor systems using a radioactive tracer that binds to specific brain targets. The serotonin 2A receptor (5-HT2A) agonist tracer [11C]Cimbi-36 enables measurement of the active-state 5-HT2A receptor, which is highly expressed in cortical regions implicated in mood regulation. When combined with a pharmacological challenge that acutely increases serotonin levels, changes in [11C]Cimbi-36 binding can be used to estimate serotonin release capacity across different brain regions. Previous work using an amphetamine challenge with [11C]Cimbi-36 has shown reduced serotonin release capacity in the frontal cortex of patients with depression compared with healthy controls, providing preliminary support for the serotonin deficiency hypothesis. However, amphetamine releases multiple neurotransmitters in addition to serotonin, limiting the ability to attribute these effects specifically to serotonergic dysfunction. Dl-fenfluramine is a more selective serotonin-releasing agent and therefore offers a targeted approach to probe serotonin release in the human brain. This case-control observational study will compare serotonin release capacity between unmedicated adults with Major Depressive Disorder (MDD) and healthy control participants using dl-fenfluramine challenge combined with [11C]Cimbi-36 PET imaging. The primary objective is to test whether individuals with MDD show reduced fenfluramine-induced serotonin release, indexed by changes in [11C]Cimbi-36 binding, relative to healthy controls. Secondary objectives include exploring how multimodal imaging, blood biomarkers, and behavioural measures relate to serotonin release capacity and depressive symptom severity. Following completion of imaging, participants with MDD who will start SSRI treatment as part of their usual clinical care will be followed for 8 weeks with remote assessments. The study will examine whether baseline measures of serotonin release capacity predict subsequent clinical response to SSRIs, defined primarily by change in clinician-rated depression scores over the treatment period. Together, these data aim to provide a more precise test of the serotonin deficiency hypothesis of depression and to identify potential biomarkers of SSRI treatment response in MDD.
- Állapot (regiszter)
- Toborzás még nem indult
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 46 (tervezett)
- Első benyújtás
- 2026. jún. 2.
- Kezdés
- 2026. júl. 1.
- Elsődleges befejezés
- 2028. júl.
- Fő szponzor
- Imperial College Healthcare NHS Trust
- Betegségek
- Depresszió
- NCT-szám
- NCT07651293
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó
- Tervezett résztvevők: 46
- 2026. júl. 1. és az elsődleges befejezés (2028. júl.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Ongoing treatment with medication that, in the opinion of the investigator, would compromise participant safety or the scientific integrity of the study, including but not limited to compounds known to interact with the serotonin 2A (5-HT2A) receptor or to have a significant effect on the synthesis and/or release of serotonin (5-HT).
- Use of illicit compounds in the 3 months before consent, including but not limited to classic psychedelics, stimulants, 3,4-methylenedioxymethamphetamine (MDMA), and cannabis.
- Contraindications to the administration of dl-fenfluramine include medications that have a significant effect on the synthesis and/or release of 5-HT.
- Participation in another research study involving ionising radiation exceeding 10 mSv within the last year.
- Contraindications to magnetic resonance imaging (MRI) scans include, but are not limited to, pacemakers, recent metallic implants, foreign bodies in the eye, or other contraindications identified by a standard pre-MRI questionnaire.
Más betegség
- Presence of a general medical or psychiatric condition (excluding MDD in the relevant population), as revealed by a physical and psychiatric examination, which, in the opinion of the Principal Investigator (PI), would impair the safety of the participant or the scientific integrity of the study.
- Contraindications to blood sampling and/or arterial cannulation, including but not limited to peripheral vascular disease or Raynaud's phenomenon.
- Claustrophobia or any other condition that would render the participant incapable of undergoing MRI/PET scanning.
- History of suicide attempts requiring hospitalisation.
- History of an Axis I psychiatric diagnosis.
- History of a neurological or general medical illness that, in the opinion of the investigator, would compromise participant safety or the scientific integrity of the study.
Egyéb
- Unwillingness or inability to follow the procedures outlined in the protocol.
- The participant is mentally or legally incapacitated.
- Abnormal Allen's test and/or prolonged Prothrombin Time (PT), due to the arterial cannulation required for the positron emission tomography (PET) scans.
- Pregnancy or breastfeeding.
- Exclusion Criterion for MDD Participants:
Kiket keres a vizsgálat
- Aged 21 years and over.
- Able to lie comfortably on their back for scanning.
- Participants must agree to use one of the contraception methods listed in Appendix 1.
- Capable of providing written informed consent and willing to comply with the requirements and restrictions listed in the consent form.
- Able to read, comprehend, and record information written in English.
- Able to access the internet through their own electronic device.
- Major depressive episode diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as moderate to severe.
- Scoring above 20 on the Montgomery-Åsberg Depression Rating Scale (MADRS).
- Have never taken antidepressants, or are currently unmedicated for at least 8 weeks before signing the informed consent form.
- Not classified as treatment-resistant.
- Ongoing relationship with a general practitioner (GP) or other healthcare professional.
- Healthy as determined by a responsible physician, based on a medical evaluation including medical history, physical examination, and laboratory tests.
Életkor a regiszterben: 21 év – - · Nem: nők és férfiak · Egészséges önkénteseket is fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| entre for Psychedelics Research, Division of Psychiatry Imperial College London, Level 2, Commonwealth Building, Hammersmith Campus, Du Cane Road, London Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát | London | Egyesült Királyság | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.